Navigation Links
Fox Chase researchers discover novel role of the NEDD9 gene in early stages of breast cancer
Date:1/14/2013

PHILADELPHIA, PA (January 14, 2013)Breast cancer is the second leading cause of cancer deaths among women in the United States. Many of these deaths occur when there is an initial diagnosis of invasive or metastatic disease. A protein called NEDD9which regulates cell migration, division and survivalhas been linked to tumor invasion and metastasis in a variety of cancers. Researchers at Fox Chase Cancer Center have now shown that NEDD9 plays a surprising role in the early stages of breast tumor development by controlling the growth of progenitor cells that give rise to tumors. The findings, published in the journal Oncogene on January 14, 2013, could lead to personalized treatment strategies for women with breast cancer based on the levels of NEDD9 in their tumors.

"For several years, NEDD9 has been linked to tumor metastasis and invasion at later stages. This is the first study that really shows how important NEDD9 can be for the initiation of tumors in breast cancer, and to link this initiation process to progenitor cells," says lead study author Joy Little, PhD, a postdoctoral fellow at Fox Chase who works in the laboratory of senior study investigator Erica A. Golemis, PhD, Deputy Chief Scientific Officer and Vice President at Fox Chase.

In the study, Little, Golemis and their collaborators mated mice without the NEDD9 gene to mice engineered to develop HER2+ mammary tumors and unexpectedly found that these mice were largely resistant to tumor formation. Only 18% of the mice developed mammary tumors, compared with 80% of mice that had a functional NEDD9 gene. In contrast to previous research findings showing that an increase in NEDD9 levels promotes tumor aggressiveness, the researchers found that loss of NEDD9 had little effect on tumor metastasis, indicating that it is not required for this process in this specific context. Once formed, the tumors in mice lacking NEDD9 grew rapidly, suggesting that it either plays a less important role at later stages of tumor growth or tumors undergo compensatory changes that allow them to bypass the need for NEDD9.

Importantly, mice lacking NEDD9 showed a significant reduction in progenitor cell populations in the mammary gland compared with mice that had a functional NEDD9 gene. Progenitor cells from NEDD9-null mice were less likely to form three-dimensional mammospheres in culture, but proliferated at the same rate as cells from control mice. The loss of Nedd9 also made progenitor cells more sensitive to lower doses of two tumor-inhibiting drugsa Food and Drug Administration-approved Src inhibitor called dasatinib, and a focal adhesion kinase inhibitor from a class of drugs currently being tested in clinical trials for the treatment of cancer. These findings suggest that these types of drugs would more effectively control breast cancer tumors with low levels of NEDD9.

"Eventually, with a biopsy, you may be able to get a read-out of all the mutations that a tumor has, and each one would potentially dictate whether or not a certain line of therapy would work for a specific tumor," Little says. "If NEDD9 levels are higher in a particular tumor, we could potentially determine whether or not it would be more sensitive to specific inhibitors."

To follow up on this work, the researchers plan to determine the mechanisms by which NEDD9 controls tumor formation, and examine whether NEDD9 plays a similar role in early stages of other types of cancer.


'/>"/>
Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Fox Chase researchers find no disparities in imaging before breast cancer surgery
2. Medtronic Infuse Bone Graft Questioned As Allegations Unfold – Bisnar
3. Chase Attorneys Offer Free Consultations
4. Lax gun ownership laws could impact ability of high-risk individuals to purchase firearms
5. SOLCO Energy’s New Corporate Solar Lens Purchase Program is Helping Businesses Soar High Above the Fiscal Tax Cliff
6. Cox Pools Introduces "Simplicity of Pool Purchase" Concept
7. Most Consumers Who Purchase a Vapor Steam Cleaner From 1-800-GO-VAPOR.com Choose a Ladybug, Company Announces
8. Top Provider of Hearing Aids in Salt Lake City UT, Advanced Hearing Center, Now Offers a 36-Month Supply of Batteries with the Purchase of Any Hearing Aid
9. Cancer Genome Institute at Fox Chase among first to offer clinical blueprint of cancer genes
10. Fox Chase receives grant for community-based patient navigation services
11. NIH awards $20 million over 5 years to train next generation of global health researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... ... manicurist from Greet, S.C., wants to offer people a new way to care for their ... feet, so I know the importance of proper foot care," he said. "In order to ... , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms of his ...
(Date:3/30/2017)... ... March 30, 2017 , ... This morning, more than 275 ... their support for an independent Vaccine Safety Commission. Five of the signers of ... will hold a press conference at 9:00 AM Friday, March 31 at ...
(Date:3/29/2017)... ... ... In the United States alone, up to 36% of primary brain tumors ... brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known to grow ... options, the San Diego Gamma Knife Center offers a precision-medicine based solution ...
(Date:3/29/2017)... ... ... Grass pollen is the main cause of hay fever in the United States, with an ... runs from May to July each year; with the worst time for sufferers being June ... balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in ...
(Date:3/29/2017)... ... 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are big fans ... been used for thousands of years. , "The West has caught on, and has ... How to Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... report to their offering. ... The global gas chromatograph market to grow at ... The report, Global Gas Chromatograph Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:3/29/2017)... EAST HANOVER, N.J. , March 29, 2017 ... and Drug Administration (FDA) has accepted the company,s ... review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen ... refractory (r/r) pediatric and young adult patients with ... first BLA submission by Novartis for a CAR-T. ...
(Date:3/29/2017)... 2017 Research and Markets has announced the addition ... at Proton Therapy Centers & Forecast" report to their offering. ... The South Korean Proton Therapy ... size in 2016. The Untapped Proton Therapy Market for South ... 2016. Proton Therapy plays an important role in delivering ...
Breaking Medicine Technology: